Biogen (BIIB) Projected to Post Earnings on Thursday

Biogen (NASDAQ:BIIB) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect Biogen to post earnings of $3.59 per share and revenue of $2.25 billion for the quarter. Biogen has set its FY 2025 guidance at 15.250-16.250 EPS.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. On average, analysts expect Biogen to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $120.17 on Wednesday. Biogen has a 1-year low of $110.04 and a 1-year high of $238.00. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The business has a fifty day moving average price of $131.78 and a 200-day moving average price of $148.18. The company has a market capitalization of $17.59 billion, a PE ratio of 10.74, a PEG ratio of 1.51 and a beta of 0.06.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Sanford C. Bernstein initiated coverage on Biogen in a report on Tuesday, February 11th. They set a “market perform” rating and a $160.00 price target for the company. Scotiabank lowered their target price on shares of Biogen from $244.00 to $224.00 and set a “sector outperform” rating on the stock in a research note on Thursday, February 13th. Bank Of America (Bofa) reduced their price target on shares of Biogen from $178.00 to $163.00 and set a “neutral” rating for the company in a research note on Tuesday, February 11th. Piper Sandler reduced their price target on shares of Biogen from $135.00 to $115.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Morgan Stanley reduced their price target on shares of Biogen from $157.00 to $152.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 9th. Twenty investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $201.93.

Insider Buying and Selling at Biogen

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.